Healthcare industry reported 85 deals worth $30 billion in Feb 2021
Three big ticket deals contribute 74 per cent of total deal value in Feb 2021
In February 2021, the healthcare industry reported 85 deals worth $30 billion as compared to last 12-month average (February 2020 to January 2021) of 88 deals worth $17.3 billion.
ICON, a provider of outsourced development services to the biotechnology, pharmaceutical and medical device industries is set to acquire PRA Health Sciences, a contract research organisation engaged in providing outsourced clinical development and data solution services for approximately $12 billion; Jazz Pharmaceuticals, a biopharma company is set to acquire GW Pharmaceuticals, also a biopharma company for $7.2 billion and Horizon Therapeutics, a biopharma company is set to acquire Viela Bio, a biotech company specialised in discovery, development and commercialisation of novel treatments for autoimmune and severe inflammatory diseases for $3 billion are the three major deals which contributed 74 per cent of the total deal value in February 2021.
| Deal Date | Acquirer (s) | Target | Deal Value ($ m) |
| 24-Feb-21 | ICON Plc (Ireland) | PRA Health Sciences Inc (US) | 12,000.0 |
| 3-Feb-21 | Jazz Pharmaceuticals Plc(Ireland) | GW Pharmaceuticals Plc (United Kingdom) | 7,200.0 |
| 1-Feb-21 | Horizon Therapeutics Plc(Ireland) | Viela Bio Inc (US) | 3,050.0 |
| 25-Feb-21 | Merck & Co Inc (US) | Pandion Therapeutics Inc (US) | 1,850.0 |
| 26-Feb-21 | Teijin Pharma Ltd (Japan) | Portfolio of Diabetes Products (Japan) | 1,252.8 |
VC investments decreased by 34.7 per cent in Feb 2021, compared to Jan 2021
The healthcare industry reported 88 venture capital (VC) deals worth $3.2billion in February 2021, compared to the last 12-month average (February 2020 to January 2021) of 125 deals worth $3.5 billion.
Centessa Pharmaceuticals, a biopharma company raising $250 million in series A round of financing; Clover Biopharmaceuticals, a clinical-stage biotechnology company raising $230 million in series C round of financing to support the continued development and expansion of its pipeline of protein-based vaccines and biologic cancer therapies; Vividion Therapeutics, a biotech company raising $135 million in series C round of financing to fuel broad pipeline of precision oncology and immunology programs are the major VC deals reported in February 2021.
| Deal Date | Acquirer (s) | Target | Deal Value ($ m) |
| 16-Feb-21 | Wellington Management Company LLP; General Atlantic LLC; EcoR1 Capital LLC; Venrock Healthcare Capital Partners LP; Undisclosed Firm; Boxer Capital LLC; Cormorant Asset Management LLC; Franklin Templeton Investments; BVF Partners LP; Samsara BioCapital LLC; Janus Henderson Investors; LifeSci Venture Partners; T Rowe Price Associates Inc; Vida Ventures LLC; Logos Global Management LLC | Centessa Pharmaceuticals Ltd (United Kingdom) | 250.0 |
| 23-Feb-21 | Temasek Holdings (Private) Ltd; Orbimed Advisors LLC; Delos Capital LLC; Oceanpine Capital; GL Ventures | Clover Biopharmaceuticals (China) | 230.0 |
| 24-Feb-21 | BlackRock Inc; Nextech Invest Ltd; RA Capital Management LP; ARCH Venture Partners LP; Versant Venture Management LLC; Driehaus Capital Management LLC; Boxer Capital LLC; Casdin Capital LLC; BVF Partners LP; Acuta Capital Partners, LLC; Mubadala Capital; T Rowe Price Associates Inc; Surveyor Capital Ltd; SoftBank Investment Advisers; Logos Global Management LLC; Woodline Partners; Avoro Capital Advisors LLC | Vividion Therapeutics Inc (US) | 135.0 |
| 24-Feb-21 | OrbiMed Asia Partners; Oceanpine Capital | Yisheng Biopharma Co Ltd (China) | 130.0 |
| 10-Feb-21 | Franklin Resources Inc; Viking Global Investors LP; RA Capital Management LP; Atlas Venture Inc; Canaan Partners; Perceptive Advisors LLC; Boxer Capital LLC; BVF Partners LP; Janus Henderson Investors; T Rowe Price Associates Inc; Access Biotechnology | Day One Biopharmaceuticals Inc (US) | 130.0 |
Source: GlobalData
- Advertisement -